PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE POTENTIAL CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDI) WITH SELUMETINIB.

Zhou L.; Cohen-Rabbie S.; Vishwanathan K.; Schalkwijk S.; Tomkinson H.; Al-Huniti N.; Zhou D.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE POTENTIAL CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDI) WITH SELUMETINIB.

【24h】

PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE POTENTIAL CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDI) WITH SELUMETINIB.

机译：基于生理学的药代动力学（PBPK）建模，以评估塞卢米替尼的潜在CYP介导的药物 - 药物相互作用（DDI）。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2020年第s1期|共2页
作者
Zhou L.; Cohen-Rabbie S.; Vishwanathan K.; Schalkwijk S.; Tomkinson H.; Al-Huniti N.; Zhou D.;
展开▼
作者单位

AstraZeneca Waltham MA USA;

AstraZeneca Cambridge England;

AstraZeneca Boston MA USA;

AstraZeneca Cambridge England;

AstraZeneca Cambridge England;

AstraZeneca Boston MA USA;

AstraZeneca Boston MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE POTENTIAL CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDI) WITH SELUMETINIB. [J] . Zhou L., Cohen-Rabbie S., Vishwanathan K., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：基于生理学的药代动力学（PBPK）建模，以评估塞卢米替尼的潜在CYP介导的药物 - 药物相互作用（DDI）。
2. A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR SIMULATION OF NALOXEGOL PHARMACOKINETICS AND DRUG-DRUG INTERACTION (DDI) POTENTIAL [J] . Zhou D., Bui K., Sostek M., Clinical Pharmacology and Therapeutics . 2014,第Suppla1期

机译：基于生理学的药代动力学（PBPK）模型，用于模拟纳洛西尔的药代动力学和药物相互作用（DDI）势
3. EVALUATION OF CYP3A4-MEDIATED AND TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION (DDI) POTENTIAL FOR PEMIGATINIB USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING. [J] . Ji T., Zhang Y., Overholt H., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：使用生理基础的药代动力学（PBPK）建模，评价CYP3A4介导和转运蛋白 - 药物 - 药物相互作用（DDI）潜力的磷酸胍潜力。
4. Physiologically-based Pharmacokinetic (PBPK) Model of TiO_2 Nanoparticles' Bio-distribution in Rat Tissues [C] . T. Laomettachit, M. Liangruksa Annual NSTI nanotechnology conference and expo;TechConnect world innovation conference expo . 2014

机译：TiO_2纳米粒子在大鼠组织中的生物分布的基于生理的药代动力学（PBPK）模型
5. In Vitro-In Vivo Assessment of Repaglinide Metabolism and Drug-Drug Interactions: Towards a Physiologically-Based Pharmacokinetic Model [D] . Thule S?ll, Carolina Maria. 2013

机译：瑞格列奈代谢和药物-药物相互作用的体外评估：建立基于生理学的药代动力学模型
6. Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin [O] . Min-Ho Park, Seok-Ho Shin, Jin-Ju Byeon, 2017

机译：基于生理学药代动力学（PBPK）建模方法的药代动力学和药物相互作用的预测：以咖啡因和环丙沙星为例
7. USING SEMIPHYSIOLOGICALLY-BASED PHARMACOKINETIC (SEMI-PBPK) MODELING TO EXPLORE THE IMPACT OF DIFFERENCES BETWEEN THE INTRAVENOUS (IV) AND ORAL (PO) ROUTE OF ADMINISTRATION ON THE MAGNITUDE AND TIME COURSE OF CYP3A-MEDIATED METABOLIC DRUG-DRUG INTERACTIONS (DDI) USING MIDAZOLAM (MDZ) AS PROTOTYPICAL SUBSTRATE AND FLUCONAZOLE (FLZ) AND ERYTHROMYCIN (ERY) AS PROTOTYPICAL INHIBITORS [O] . Li Mengyao 2016

机译：使用基于半生理学的药代动力学（SEMI-PBPK）模型来探讨静脉（IV）和口服（PO）给药途径对经CYP3A药物代谢药物治疗（药物）的幅度和时间过程的影响咪达唑仑（MDZ）作为原型基质，氟康唑（FLZ）和红霉素（ERY）作为原型抑制剂
8. Providing a Theoretical Basis for Nanotoxicity Risk Analysis Departing from Traditional Physiologically-Based Pharmacokinetic (PBPK) Modeling [R] . Yamamoto, D. P. 2010

机译：为传统的基于生理学的药代动力学（pBpK）建模的纳米毒性风险分析提供理论基础

PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE POTENTIAL CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDI) WITH SELUMETINIB.

著录项

相似文献

相关主题

期刊订阅